Our findings also suggest that SRF231 could be more effective in eliminating cancer cells that are resistant to venetoclax, provided that these cells are not simultaneously treated with venetoclax in a scenario where venetoclax does not induce any cytotoxic effect but rather oncogenic effect through MCL-1 upregulation. This evidence concerns the gene MCL1 and cancer.